rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2024-109-117rsp-3520Research ArticleПЕДИАТРИЧЕСКАЯ РЕВМАТОЛОГИЯPEDIATRIC RHEUMATOLOGYНарушения психического здоровья у детей с ревматическими заболеваниямиMental disorders in children with rheumatic diseaseshttps://orcid.org/0000-0003-4750-5623СантимовА. В.SantimovA. V.

Сантимов Андрей Вячеславович

194100, Санкт-Петербург, ул. Литовская, 2

Andrei V. Santimov

194100, Saint-Petersburg, Litovskaya str., 2

a.santimoff@gmail.comhttps://orcid.org/0000-0001-5967-4315ГречаныйС. В.GrechanyiS. V.

194100, Санкт-Петербург, ул. Литовская, 2

Severin V. Grechanyi

194100, Saint-Petersburg, Litovskaya str., 2

https://orcid.org/0000-0002-7571-5460НовикГ. А.NovikG. A.

194100, Санкт-Петербург, ул. Литовская, 2

Gennady A. Novik

194100, Saint-Petersburg, Litovskaya str., 2

ФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава РоссииРоссияSt. Petersburg State Pediatric Medical UniversityRussian Federation202401032024621109117Copyright © Сантимов А.В., Гречаный С.В., Новик Г.А., 20242024Сантимов А.В., Гречаный С.В., Новик Г.А.Santimov A.V., Grechanyi S.V., Novik G.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3520

У детей, страдающих ревматическими заболеваниями, распространенность сопутствующих нарушений психического здоровья значительно выше, чем в общей популяции. При этом психиатрическая коморбидность в детской ревматологии по-прежнему остается малоизученной, а подходы к терапии нарушений психического здоровья при ревматических заболеваниях у детей четко не определены. В обзорной статье рассмотрены имеющиеся на сегодняшний день данные о распространенности нарушений психического здоровья при ювенильном идиопатическом артрите, системной красной волчанке с ювенильным дебютом и ювенильной первичной фибромиалгии. Представлены данные о проведенных клинических исследованиях эффективности и безопасности психотерапии и психофармакотерапии; обсуждаются также возможные перспективы применения генно-инженерных биологических препаратов для лечения депрессии, коморбидной ревматическим заболеваниям у детей.

The prevalence of concomitant mental disorders in children with rheumatic diseases is notably higher than in the overall population. However, psychiatric comorbidity in pediatric rheumatology remains poorly understood, whereas approaches to mental disorders therapy in children with rheumatic diseases are not clearly defined. The review article considers currently available data on the mental disorders prevaling in patients with juvenile idiopathic arthritis, juvenile-onset systemic lupus erythematosus and juvenile primary fibromyalgia. The article provides data on the efficacy and safety studies of psychotherapy and psychopharmacotherapy. It also discusses application prospects of biological disease-modifying antirheumatic drugs for treatment of comorbid depression in children with rheumatic diseases.

нарушения психического здоровьяювенильный идиопатический артритсистемная красная волчанка с ювенильным дебютомювенильная первичная фибромиалгиятревогадепрессияпсихотерапияпсихофармакотерапиягенно-инженерные биологические препаратыmental disordersjuvenile idiopathic arthritisjuvenile-onset systemic lupus erythematosusjuvenile primary fibromyalgiaanxietydepressionpsychotherapypsychopharmacotherapybiological disease-modifying antirheumatic drugsReferencesKostev K, Teichgräber F, Konrad M, Jacob L. Association between chronic somatic conditions and depression in children and adolescents: A retrospective study of 13,326 patients. J Affect Disord. 2019;245:697-701. doi: 10.1016/j.jad.2018.11.014Kostev K, Teichgräber F, Konrad M, Jacob L. Association between chronic somatic conditions and depression in children and adolescents: A retrospective study of 13,326 patients. J Affect Disord. 2019;245:697-701. doi: 10.1016/j.jad.2018.11.014Williams NA, Burnfield JM. Psychological difficulties and parental well-being in children with musculoskeletal problems in the 2011/2012 National Survey of Children’s Health. Rehabil Psychol. 2019;64(1):87-97. doi: 10.1037/rep0000251Williams NA, Burnfield JM. Psychological difficulties and parental well-being in children with musculoskeletal problems in the 2011/2012 National Survey of Children’s Health. Rehabil Psychol. 2019;64(1):87-97. doi: 10.1037/rep0000251Miller AH, Raison CL. The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22-34. doi: 10.1038/nri.2015.5Miller AH, Raison CL. The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22-34. doi: 10.1038/nri.2015.5Suneson K, Lindahl J, Chamli Hårsmar S, Söderberg G, Lindqvist D. Inflammatory depression-mechanisms and non-pharmacological interventions. Int J Mol Sci. 2021;22(4):1640. doi: 10.3390/ijms22041640Suneson K, Lindahl J, Chamli Hårsmar S, Söderberg G, Lindqvist D. Inflammatory depression-mechanisms and non-pharmacological interventions. Int J Mol Sci. 2021;22(4):1640. doi: 10.3390/ijms22041640Davis AM, Rubinstein TB, Rodriguez M, Knight AM. Mental health care for youth with rheumatologic diseases – bridging the gap. Pediatr Rheumatol Online J. 2017;15(1):85. doi: 10.1186/s12969-017-0214-9Davis AM, Rubinstein TB, Rodriguez M, Knight AM. Mental health care for youth with rheumatologic diseases – bridging the gap. Pediatr Rheumatol Online J. 2017;15(1):85. doi: 10.1186/s12969-017-0214-9Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767-778. doi: 10.1016/S0140-6736(07)60363-8Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767-778. doi: 10.1016/S0140-6736(07)60363-8Korte-Bouws GAH, Albers E, Voskamp M, Hendriksen H, de Leeuw LR, Güntürkün O, et al. Juvenile arthritis patients suffering from chronic inflammation have increased activity of both IDO and GTP-CH1 pathways but decreased BH4 efficacy: Implications for well-being, including fatigue, cognitive impairment, anxiety, and depression. Pharmaceuticals (Basel). 2019;12(1):9. doi: 10.3390/ph12010009Korte-Bouws GAH, Albers E, Voskamp M, Hendriksen H, de Leeuw LR, Güntürkün O, et al. Juvenile arthritis patients suffering from chronic inflammation have increased activity of both IDO and GTP-CH1 pathways but decreased BH4 efficacy: Implications for well-being, including fatigue, cognitive impairment, anxiety, and depression. Pharmaceuticals (Basel). 2019;12(1):9. doi: 10.3390/ph12010009Reda MM, Hosny E, AbuSenna H. Psychiatric morbidity in patients with rheumatoid juvenile arthritis: A SPECT study. Middle East Curr Psychiat. 2011;18(3):132-137. doi: 10.1097/01.XME.0000398422.59986.78Reda MM, Hosny E, AbuSenna H. Psychiatric morbidity in patients with rheumatoid juvenile arthritis: A SPECT study. Middle East Curr Psychiat. 2011;18(3):132-137. doi: 10.1097/01.XME.0000398422.59986.78Hanns L, Cordingley L, Galloway J, Norton S, Carvalho LA, Christie D, et al. Depressive symptoms, pain and disability for adolescent patients with juvenile idiopathic arthritis: Results from the Childhood Arthritis Prospective Study. Rheumatology (Oxford). 2018;57(8):1381-1389. doi: 10.1093/rheumatology/key088Hanns L, Cordingley L, Galloway J, Norton S, Carvalho LA, Christie D, et al. Depressive symptoms, pain and disability for adolescent patients with juvenile idiopathic arthritis: Results from the Childhood Arthritis Prospective Study. Rheumatology (Oxford). 2018;57(8):1381-1389. doi: 10.1093/rheumatology/key088El-Najjar AR, Negm MG, El-Sayed WM. The relationship between depression, disease activity and physical function in juvenile idiopathic arthritis patients in Zagazig University Hospitals – Egypt. Egypt Rheumatologist. 2014;36(3):145-150. doi: 10.1016/j.ejr.2014.01.001El-Najjar AR, Negm MG, El-Sayed WM. The relationship between depression, disease activity and physical function in juvenile idiopathic arthritis patients in Zagazig University Hospitals – Egypt. Egypt Rheumatologist. 2014;36(3):145-150. doi: 10.1016/j.ejr.2014.01.001Tarakci E, Yeldan I, Kaya Mutlu E, Baydogan SN, Kasapcopur O. The relationship between physical activity level, anxiety, depression, and functional ability in children and adolescents with juvenile idiopathic arthritis. Clin Rheumatol. 2011;30(11):1415-1420. doi: 10.1007/s10067-011-1832-0Tarakci E, Yeldan I, Kaya Mutlu E, Baydogan SN, Kasapcopur O. The relationship between physical activity level, anxiety, depression, and functional ability in children and adolescents with juvenile idiopathic arthritis. Clin Rheumatol. 2011;30(11):1415-1420. doi: 10.1007/s10067-011-1832-0Fair DC, Rodriguez M, Knight AM, Rubinstein TB. Depression and anxiety in patients with juvenile idiopathic arthritis: Current insights and impact on quality of life, a systematic review. Open Access Rheumatol. 2019;11:237-252. doi: 10.2147/OARRR. S174408Fair DC, Rodriguez M, Knight AM, Rubinstein TB. Depression and anxiety in patients with juvenile idiopathic arthritis: Current insights and impact on quality of life, a systematic review. Open Access Rheumatol. 2019;11:237-252. doi: 10.2147/OARRR. S174408Сантимов АВ, Часнык ВГ, Гречаный СВ. Психометрическая оценка хронического болевого синдрома при ювенильном идиопатическом артрите. Педиатр. 2019;10(3):25-30. [Santimov AV, Chasnyk VG, Grechanyi SV. Psychometric assessment of chronic pain syndrome in juvenile idiopathic arthritis. Pediatrician (St. Petersburg). 2019;10(3):25-30 (In Russ.)]. doi: 10.17816/PED10325-30Сантимов АВ, Часнык ВГ, Гречаный СВ. Психометрическая оценка хронического болевого синдрома при ювенильном идиопатическом артрите. Педиатр. 2019;10(3):25-30. [Santimov AV, Chasnyk VG, Grechanyi SV. Psychometric assessment of chronic pain syndrome in juvenile idiopathic arthritis. Pediatrician (St. Petersburg). 2019;10(3):25-30 (In Russ.)]. doi: 10.17816/PED10325-30Сантимов АВ, Часнык ВГ, Гречаный СВ. Уровень тревоги и депрессии у детей и подростков с хроническим болевым синдромом (на примере ювенильного идиопатического артрита). Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2019;4-2:78-86. doi: 10.31363/2313-7053-2019-4-2-78-86Santimov AV, Chasnyk VG, Grechanyi SV. The level of anxiety and depression in children and adolescents with chronic pain syndrome (on the example of juvenile idiopathic arthritis). V.M. Bekhterev Review of Psychiatry and Medical Psychology. 2019;4-2:78-86 (In Russ.) doi: 10.31363/2313-7053-2019-4-2-78-86Зубарева ЕС, Генералова ДД, Сантимов АВ, Новик ГА, Тамразова ОБ, Гречаный СВ. Выявление нарушений психического здоровья при ювенильном идиопатическом артрите с хроническим болевым синдромом. Педиатрия им. Г.Н. Сперанского. 2023;102(4):147-158. doi: 10.24110/0031-403X-2023-102-4-147-158Zubareva ES, Generalova DD, Santimov AV, Novik GA, Tamrazova OB, Grechanyi SV. Mental health disorders identification in pediatric patients with juvenile idiopathic arthritis with chronic pain syndrome. Pediatria n.a. G.N. Speransky. 2023;102(4):147-158 (In Russ.) doi: 10.24110/0031-403X-2023-102-4-147-158Kyllönen MS, Ebeling H, Kautiainen H, Puolakka K, Vähäsalo P. Psychiatric disorders in incident patients with juvenile idiopathic arthritis – a case-control cohort study. Pediatr Rheumatol Online J. 2021;19(1):105. doi: 10.1186/s12969-021-00599-xKyllönen MS, Ebeling H, Kautiainen H, Puolakka K, Vähäsalo P. Psychiatric disorders in incident patients with juvenile idiopathic arthritis – a case-control cohort study. Pediatr Rheumatol Online J. 2021;19(1):105. doi: 10.1186/s12969-021-00599-xBerthold E, Dahlberg A, Jöud A, Tydén H, Månsson B, Kahn F, et al. The risk of depression and anxiety is not increased in individuals with juvenile idiopathic arthritis – results from the SouthSwedish Juvenile Idiopathic Arthritis Cohort. Pediatr Rheumatol Online J. 2022;20(1):114. doi: 10.1186/s12969-022-00765-9Berthold E, Dahlberg A, Jöud A, Tydén H, Månsson B, Kahn F, et al. The risk of depression and anxiety is not increased in individuals with juvenile idiopathic arthritis – results from the SouthSwedish Juvenile Idiopathic Arthritis Cohort. Pediatr Rheumatol Online J. 2022;20(1):114. doi: 10.1186/s12969-022-00765-9Delcoigne B, Horne A, Reutfors J, Askling J. Risk of psychiatric disorders in juvenile idiopathic arthritis: Population- and siblingcontrolled cohort and cross-sectional analyses. ACR Open Rheumatol. 2023;5(5):277-284. doi: 10.1002/acr2.11549Delcoigne B, Horne A, Reutfors J, Askling J. Risk of psychiatric disorders in juvenile idiopathic arthritis: Population- and siblingcontrolled cohort and cross-sectional analyses. ACR Open Rheumatol. 2023;5(5):277-284. doi: 10.1002/acr2.11549Mann CM, Schanberg LE, Wang M, von Scheven E, Lucas N, Hernandez A, et al. Identifying clinically meaningful severity categories for PROMIS pediatric measures of anxiety, mobility, fatigue, and depressive symptoms in juvenile idiopathic arthritis and childhood-onset systemic lupus erythematosus. Qual Life Res. 2020;29(9):2573-2584. doi: 10.1007/s11136-020-02513-6Mann CM, Schanberg LE, Wang M, von Scheven E, Lucas N, Hernandez A, et al. Identifying clinically meaningful severity categories for PROMIS pediatric measures of anxiety, mobility, fatigue, and depressive symptoms in juvenile idiopathic arthritis and childhood-onset systemic lupus erythematosus. Qual Life Res. 2020;29(9):2573-2584. doi: 10.1007/s11136-020-02513-6Kısaarslan AP, Çiçek SÖ, Batu ED, Şahin S, Gürgöze MK, Çetinkaya SB, et al. Neuropsychiatric involvement in juvenileonset systemic lupus erythematosus: A multicenter study. Joint Bone Spine. 2023;90(4):105559. doi: 10.1016/j.jbspin.2023.105559Kısaarslan AP, Çiçek SÖ, Batu ED, Şahin S, Gürgöze MK, Çetinkaya SB, et al. Neuropsychiatric involvement in juvenileonset systemic lupus erythematosus: A multicenter study. Joint Bone Spine. 2023;90(4):105559. doi: 10.1016/j.jbspin.2023.105559Natoli V, Charras A, Hahn G, Hedrich CM. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus (jSLE). Mol Cell Pediatr. 2023;10(1):5. doi: 10.1186/s40348-023-00161-7Natoli V, Charras A, Hahn G, Hedrich CM. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus (jSLE). Mol Cell Pediatr. 2023;10(1):5. doi: 10.1186/s40348-023-00161-7Donnelly C, Cunningham N, Jones JT, Ji L, Brunner HI, Kashikar-Zuck S. Fatigue and depression predict reduced health-related quality of life in childhood-onset lupus. Lupus. 2018;27(1):124- 133. doi: 10.1177/0961203317716317Donnelly C, Cunningham N, Jones JT, Ji L, Brunner HI, Kashikar-Zuck S. Fatigue and depression predict reduced health-related quality of life in childhood-onset lupus. Lupus. 2018;27(1):124- 133. doi: 10.1177/0961203317716317Каледа МИ, Никишина ИП. Нейропсихические нарушения при системной красной волчанке с ювенильным дебютом. Научно-практическая ревматология. 2020;58(4):437-442. doi: 10.47360/1995-4484-2020-437-442Kaleda MI, Nikishina IP. Neuropsychiatric involvement in juvenileonset systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(4):437- 442 (In Russ.) doi: 10.47360/1995-4484-2020-437-442Каледа МИ, Никишина ИП, Глухова СИ, Степаненко НЮ.Нейропсихические нарушения при ювенильном дебюте системной красной волчанки: результаты ретроспективного исследования. Научно-практическая ревматология. 2020;58(2):171-177. doi: 10.14412/1995-4484-2020-171-177Kaleda MI, Nikishina IP, Glukhova SI, Stepanenko NYu. Neuropsychiatric disorders in juvenile-onset systemic lupus erythematosus: Results from a retrospective study. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(2):171-177 (In Russ.) doi: 10.14412/1995-4484-2020-171-177Кучинская ЕМ, Яковлева ЮА, Ракова МА, Любимова НА, Суспицын ЕН, Костик ММ. Системная красная волчанка с нейропсихическими проявлениями у ребенка: описание клинического случая и обзор международных рекомендаций по диагностике и лечению. Российский вестник перинатологии и педиатрии. 2021;66(1):98-105. doi: 10.21508/1027-4065-2021-66-1-98-105Kuchinskaya EM, Yakovleva YuA, Rakova MA, Lyubimova NA, Suspitsin EN, Kоstik MM. Systemic lupus erythematosus with neuropsychiatric manifestations in a child: Case report and review of the international recommendations for the diagnostics and management. Russian Bulletin of Perinatology and Pediatrics. 2021;66(1):98-105 (In Russ.) doi: 10.21508/1027-4065-2021-66-1-98-105Кучинская ЕМ, Часнык ВГ, Костик ММ. Системная красная волчанка у детей: применение формализованных методов описания течения и исхода заболевания в ретроспективном исследовании. Педиатр. 2017;8(5):35-43. doi: 10.17816/PED8535-43Kuchinskaya EM, Chasnyk VG, Kostik MM. Measures in assessment of pediatric systemic lupus erythematosus: An experience of retrospective observational study. Pediatrician (St. Petersburg). 2017;8(5):35-43 (In Russ.) doi: 10.17816/PED8535-43Giani T, Smith EM, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al.; UK JSLE Cohort Study. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: Data from the UK Juvenile-onset systemic lupus erythematosus cohort study. Lupus. 2021;30(12):1955-1965. doi: 10.1177/09612033211045050Giani T, Smith EM, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al.; UK JSLE Cohort Study. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: Data from the UK Juvenile-onset systemic lupus erythematosus cohort study. Lupus. 2021;30(12):1955-1965. doi: 10.1177/09612033211045050Knight AM, Xie M, Mandell DS. Disparities in psychiatric diagnosis and treatment for youth with systemic lupus erythematosus: Analysis of a national US Medicaid sample. J Rheumatol. 2016;43(7):1427-1433. doi: 10.3899/jrheum.150967Knight AM, Xie M, Mandell DS. Disparities in psychiatric diagnosis and treatment for youth with systemic lupus erythematosus: Analysis of a national US Medicaid sample. J Rheumatol. 2016;43(7):1427-1433. doi: 10.3899/jrheum.150967Coles ML, Weissmann R, Uziel Y. Juvenile primary fibromyalgia syndrome: Epidemiology, etiology, pathogenesis, clinical manifestations and diagnosis. Pediatr Rheumatol Online J. 2021;19(1):22. doi: 10.1186/s12969-021-00493-6Coles ML, Weissmann R, Uziel Y. Juvenile primary fibromyalgia syndrome: Epidemiology, etiology, pathogenesis, clinical manifestations and diagnosis. Pediatr Rheumatol Online J. 2021;19(1):22. doi: 10.1186/s12969-021-00493-6Kashikar-Zuck S, Parkins IS, Graham TB, Lynch AM, Passo M, Johnston M, et al. Anxiety, mood, and behavioral disorders among pediatric patients with juvenile fibromyalgia syndrome. Clin J Pain. 2008;24(7):620-626. doi: 10.1097/AJP.0b013e31816d7d23Kashikar-Zuck S, Parkins IS, Graham TB, Lynch AM, Passo M, Johnston M, et al. Anxiety, mood, and behavioral disorders among pediatric patients with juvenile fibromyalgia syndrome. Clin J Pain. 2008;24(7):620-626. doi: 10.1097/AJP.0b013e31816d7d23Conte PM, Walco GA, Kimura Y. Temperament and stress response in children with juvenile primary fibromyalgia syndrome. Arthritis Rheum. 2003;48(10):2923-2930. doi: 10.1002/art.11244Conte PM, Walco GA, Kimura Y. Temperament and stress response in children with juvenile primary fibromyalgia syndrome. Arthritis Rheum. 2003;48(10):2923-2930. doi: 10.1002/art.11244Kashikar-Zuck S, Cunningham N, Peugh J, Black WR, Nelson S, Lynch-Jordan AM, et al. Long-term outcomes of adolescents with juvenile-onset fibromyalgia into adulthood and impact of depressive symptoms on functioning over time. Pain. 2019;160(2):433-441. doi: 10.1097/j.pain.0000000000001415Kashikar-Zuck S, Cunningham N, Peugh J, Black WR, Nelson S, Lynch-Jordan AM, et al. Long-term outcomes of adolescents with juvenile-onset fibromyalgia into adulthood and impact of depressive symptoms on functioning over time. Pain. 2019;160(2):433-441. doi: 10.1097/j.pain.0000000000001415Connelly M, Weiss JE. Pain, functional disability, and their association in juvenile fibromyalgia compared to other pediatric rheumatic diseases. Pediatr Rheumatol. 2019;17(1):72. doi: 10.1186/s12969-019-0375-9Connelly M, Weiss JE. Pain, functional disability, and their association in juvenile fibromyalgia compared to other pediatric rheumatic diseases. Pediatr Rheumatol. 2019;17(1):72. doi: 10.1186/s12969-019-0375-9Weiss JE, Schikler KN, Boneparth AD, Connelly M. Demographic, clinical, and treatment characteristics of the juvenile primary fibromyalgia syndrome cohort enrolled in the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. Pediatr Rheumatol. 2019;17(1):1-8. doi: 10.1186/s12969-019-0356-zWeiss JE, Schikler KN, Boneparth AD, Connelly M. Demographic, clinical, and treatment characteristics of the juvenile primary fibromyalgia syndrome cohort enrolled in the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. Pediatr Rheumatol. 2019;17(1):1-8. doi: 10.1186/s12969-019-0356-zSiegel DM, Janeway D, Baum J. Fibromyalgia syndrome in children and adolescents: Clinical features at presentation and status at follow-up. Pediatrics. 1998;101(3 Pt 1):377-382. doi: 10.1542/peds.101.3.377Siegel DM, Janeway D, Baum J. Fibromyalgia syndrome in children and adolescents: Clinical features at presentation and status at follow-up. Pediatrics. 1998;101(3 Pt 1):377-382. doi: 10.1542/peds.101.3.377Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med. 2000;160(2):221-227. doi: 10.1001/archinte.160.2.221Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med. 2000;160(2):221-227. doi: 10.1001/archinte.160.2.221Gmuca S, Sherry DD. Fibromyalgia: Treating pain in the juvenile patient. Pediatr Drugs. 2017;19(4):325-338. doi: 10.1007/s40272-017-0233-5Gmuca S, Sherry DD. Fibromyalgia: Treating pain in the juvenile patient. Pediatr Drugs. 2017;19(4):325-338. doi: 10.1007/s40272-017-0233-5Bennett R, Nelson D. Cognitive behavioral therapy for fibromyalgia. Nat Clin Pract Rheumatol. 2006;2(8):416-424. doi: 10.1038/ncprheum0245Bennett R, Nelson D. Cognitive behavioral therapy for fibromyalgia. Nat Clin Pract Rheumatol. 2006;2(8):416-424. doi: 10.1038/ncprheum0245Kashikar-Zuck S, Ting TV, Arnold LM, Bean J, Powers SW, Graham TB, et al. Cognitive behavioral therapy for the treatment of juvenile fibromyalgia: A multisite, single-blind, randomized, controlled clinical trial. Arthritis Rheum. 2012;64(1):297-305. doi: 10.1002/art.30644Kashikar-Zuck S, Ting TV, Arnold LM, Bean J, Powers SW, Graham TB, et al. Cognitive behavioral therapy for the treatment of juvenile fibromyalgia: A multisite, single-blind, randomized, controlled clinical trial. Arthritis Rheum. 2012;64(1):297-305. doi: 10.1002/art.30644Fisher E, Law E, Dudeney J, Palermo TM, Stewart G, Eccleston C. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. 2018;9(9):CD003968. doi: 10.1002/14651858.CD003968.pub5Fisher E, Law E, Dudeney J, Palermo TM, Stewart G, Eccleston C. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. 2018;9(9):CD003968. doi: 10.1002/14651858.CD003968.pub5Сантимов АВ, Часнык ВГ, Гречаный СВ. Психотерапевтический подход к лечению хронического болевого синдрома при ювенильном идиопатическом артрите и предикторы его эффективности. Психиатрия, психотерапия и клиническая психология. 2022;13(2):138-150. doi: 10.34883/PI.2022.13.2.010Santimov AV, Chasnyk VG, Grechanyi SV. Psychotherapeutic approach to the treatment of chronic pain syndrome in juvenile idiopathic arthritis and predictors of its effectiveness. Psychiatry, Psychotherapy and Clinical Psychology. 2022;13(2):138-150 (In Russ.)]. doi: 10.34883/PI.2022.13.2.010Trachtman R, Samuels J, Wojtal E, Feldman BM. Resilience and its associations in children with systemic lupus erythematosus and juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2023;21(1):67. doi: 10.1186/s12969-023-00854-3Trachtman R, Samuels J, Wojtal E, Feldman BM. Resilience and its associations in children with systemic lupus erythematosus and juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2023;21(1):67. doi: 10.1186/s12969-023-00854-3Ross E, Abulaban K, Kessler E, Cunningham N. Non-pharmacologic therapies in treatment of childhood-onset systemic lupus erythematosus: A systematic review. Lupus. 2022;31(7):864-879. doi: 10.1177/09612033221094704Ross E, Abulaban K, Kessler E, Cunningham N. Non-pharmacologic therapies in treatment of childhood-onset systemic lupus erythematosus: A systematic review. Lupus. 2022;31(7):864-879. doi: 10.1177/09612033221094704Calandre EP, Rico-Villademoros F, Slim M. An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother. 2015;16(9):1347-1368. doi: 10.1517/14656566.2015.1047343Calandre EP, Rico-Villademoros F, Slim M. An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother. 2015;16(9):1347-1368. doi: 10.1517/14656566.2015.1047343Welsch P, Üçeyler N, Klose P, Walitt B, Häuser W. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev. 2018;2(2):CD010292. doi: 10.1002/14651858.CD010292.pub2Welsch P, Üçeyler N, Klose P, Walitt B, Häuser W. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev. 2018;2(2):CD010292. doi: 10.1002/14651858.CD010292.pub2Upadhyaya HP, Arnold LM, Alaka K, Qiao M, Williams D, Mehta R. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial. Pediatr Rheumatol Online J. 2019;17(1):27. doi: 10.1186/s12969-019-0325-6Upadhyaya HP, Arnold LM, Alaka K, Qiao M, Williams D, Mehta R. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial. Pediatr Rheumatol Online J. 2019;17(1):27. doi: 10.1186/s12969-019-0325-6Arnold LM, Bateman L, Palmer RH, Lin Y. Preliminary experience using milnacipran in patients with juvenile fibromyalgia: Lessons from a clinical trial program. Pediatr Rheumatol Online J. 2015;13:27. doi: 10.1186/s12969-015-0025-9Arnold LM, Bateman L, Palmer RH, Lin Y. Preliminary experience using milnacipran in patients with juvenile fibromyalgia: Lessons from a clinical trial program. Pediatr Rheumatol Online J. 2015;13:27. doi: 10.1186/s12969-015-0025-9Mariutto EN, Stanford SB, Kashikar-Zuck S, Welge JA, Arnold LM. An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia. J Clin Psychopharmacol. 2012;32(2):293-295. doi: 10.1097/JCP.0b013e31824858dcMariutto EN, Stanford SB, Kashikar-Zuck S, Welge JA, Arnold LM. An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia. J Clin Psychopharmacol. 2012;32(2):293-295. doi: 10.1097/JCP.0b013e31824858dcNishishinya B, Urrútia G, Walitt B, Rodriguez A, Bonfill X, Alegre C, et al. Amitriptyline in the treatment of fibromyalgia: A systematic review of its efficacy. Rheumatology (Oxford). 2008;47(12):1741-1746. doi: 10.1093/rheumatology/ken317Nishishinya B, Urrútia G, Walitt B, Rodriguez A, Bonfill X, Alegre C, et al. Amitriptyline in the treatment of fibromyalgia: A systematic review of its efficacy. Rheumatology (Oxford). 2008;47(12):1741-1746. doi: 10.1093/rheumatology/ken317Migliorini F, Maffulli N, Knobe M, Tenze G, Aljalloud A, Colarossi G. Pregabalin administration in patients with fibromyalgia: A Bayesian network meta-analysis. Sci Rep. 2022;12(1):12148. doi: 10.1038/s41598-022-16146-xMigliorini F, Maffulli N, Knobe M, Tenze G, Aljalloud A, Colarossi G. Pregabalin administration in patients with fibromyalgia: A Bayesian network meta-analysis. Sci Rep. 2022;12(1):12148. doi: 10.1038/s41598-022-16146-xArnold LM, Goldenberg DL, Stanford SB, Lalonde JK, Sandhu HS, Keck PE Jr, et al. Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56(4):1336-1344. doi: 10.1002/art.22457Arnold LM, Goldenberg DL, Stanford SB, Lalonde JK, Sandhu HS, Keck PE Jr, et al. Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56(4):1336-1344. doi: 10.1002/art.22457Egunsola O, Wylie CE, Chitty KM, Buckley NA. Systematic review of the efficacy and safety of gabapentin and pregabalin for pain in children and adolescents. Anesth Analg. 2019;128(4):811-819. doi: 10.1213/ANE.0000000000003936Egunsola O, Wylie CE, Chitty KM, Buckley NA. Systematic review of the efficacy and safety of gabapentin and pregabalin for pain in children and adolescents. Anesth Analg. 2019;128(4):811-819. doi: 10.1213/ANE.0000000000003936Arnold LM, Schikler KN, Bateman L, Khan T, Pauer L, BhadraBrown P, et al.; Pregabalin Adolescent Fibromyalgia Study Group. Safety and efficacy of pregabalin in adolescents with fibromyalgia: A randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study. Pediatr Rheumatol Online J. 2016;14(1):46. doi: 10.1186/s12969-016-0106-4Arnold LM, Schikler KN, Bateman L, Khan T, Pauer L, BhadraBrown P, et al.; Pregabalin Adolescent Fibromyalgia Study Group. Safety and efficacy of pregabalin in adolescents with fibromyalgia: A randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study. Pediatr Rheumatol Online J. 2016;14(1):46. doi: 10.1186/s12969-016-0106-4Ting EY, Yang AC, Tsai SJ. Role of interleukin-6 in depressive disorder. Int J Mol Sci. 2020;21(6):2194. doi: 10.3390/ijms21062194Ting EY, Yang AC, Tsai SJ. Role of interleukin-6 in depressive disorder. Int J Mol Sci. 2020;21(6):2194. doi: 10.3390/ijms21062194Лисицына ТА, Вельтищев ДЮ, Лила АМ, Насонов ЕЛ. Интерлейкин 6 как патогенетический фактор, опосредующий формирование клинических проявлений, и мишень для терапии ревматических заболеваний и депрессивных расстройств. Научно-практическая ревматология. 2019;57(3):318-327. doi: 10.14412/1995-4484-2019-318-327Lisitsyna TA, Veltishchev DYu, Lila AM, Nasonov EL. Interleukin 6 as a pathogenic factor mediating clinical manifestations and a therapeutic target for rheumatic diseases and depressive disorders. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(3):318-327 (In Russ.) doi: 10.14412/1995-4484-2019-318-327Drevets WC, Wittenberg GM, Bullmore ET, Manji HK. Immune targets for therapeutic development in depression: Towards precision medicine. Nat Rev Drug Discov. 2022;21(3):224-244. doi: 10.1038/s41573-021-00368-1Drevets WC, Wittenberg GM, Bullmore ET, Manji HK. Immune targets for therapeutic development in depression: Towards precision medicine. Nat Rev Drug Discov. 2022;21(3):224-244. doi: 10.1038/s41573-021-00368-1Лисицына ТА, Абрамкин АА, Вельтищев ДЮ, Серавина ОФ, Ковалевская ОБ, Борисова АБ, и др. Эффективность олокизумаба в отношении коморбидного депрессивного расстройства у больных ревматоидным артритом: предварительные результаты исследования. Научно-практическая ревматология. 2023; 61(2):188-198. doi: 10.47360/1995-4484-2023-188-198Lisitsyna TA, Abramkin AA, Veltishchev DYu, Seravina OF, Kovalevskaya OB, Borisova AB, et al. Efficacy of olokizumab against comorbid depressive disorder in patients with rheumatoid arthritis: Preliminary results of the study. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023; 61(2):188-198 (In Russ.) doi: 10.47360/1995-4484-2023-188-198Coskun Benlidayi I. Role of inflammation in the pathogenesis and treatment of fibromyalgia. Rheumatol Int. 2019;39(5):781-791. doi: 10.1007/s00296-019-04251-6Coskun Benlidayi I. Role of inflammation in the pathogenesis and treatment of fibromyalgia. Rheumatol Int. 2019;39(5):781-791. doi: 10.1007/s00296-019-04251-6Mendieta D, De la Cruz-Aguilera DL, Barrera-Villalpando MI, Becerril-Villanueva E, Arreola R, Hernández-Ferreira E, et al. IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients. J Neuroimmunol. 2016;290:22-25. doi: 10.1016/j.jneuroim.2015.11.011Mendieta D, De la Cruz-Aguilera DL, Barrera-Villalpando MI, Becerril-Villanueva E, Arreola R, Hernández-Ferreira E, et al. IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients. J Neuroimmunol. 2016;290:22-25. doi: 10.1016/j.jneuroim.2015.11.011Ranzolin A, Duarte AL, Bredemeier M, da Costa Neto CA, Ascoli BM, Wollenhaupt-Aguiar B, et al. Evaluation of cytokines, oxidative stress markers and brain-derived neurotrophic factor in patients with fibromyalgia – A controlled cross-sectional study. Cytokine. 2016;84:25-28. doi: 10.1016/j.cyto.2016.05.011Ranzolin A, Duarte AL, Bredemeier M, da Costa Neto CA, Ascoli BM, Wollenhaupt-Aguiar B, et al. Evaluation of cytokines, oxidative stress markers and brain-derived neurotrophic factor in patients with fibromyalgia – A controlled cross-sectional study. Cytokine. 2016;84:25-28. doi: 10.1016/j.cyto.2016.05.011Pernambuco AP, Schetino LP, Alvim CC, Murad CM, Viana RS, Carvalho LS, et al. Increased levels of IL-17A in patients with fibromyalgia. Clin Exp Rheumatol. 2013;31(6 Suppl 79):S60-S63.Pernambuco AP, Schetino LP, Alvim CC, Murad CM, Viana RS, Carvalho LS, et al. Increased levels of IL-17A in patients with fibromyalgia. Clin Exp Rheumatol. 2013;31(6 Suppl 79):S60-S63.Mastrangelo F, Frydas I, Ronconi G, Kritas SK, Tettamanti L, Caraffa Al, et al. Low-grade chronic inflammation mediated by mast cells in fibromyalgia: Role of IL-37. J Biol Regul Homeost Agents. 2018;32(2):195-198.Mastrangelo F, Frydas I, Ronconi G, Kritas SK, Tettamanti L, Caraffa Al, et al. Low-grade chronic inflammation mediated by mast cells in fibromyalgia: Role of IL-37. J Biol Regul Homeost Agents. 2018;32(2):195-198.Loncharich MF, Robertson I. Anifrolumab in systemic lupus erythematosus. Drugs Today (Barc). 2023;59(2):53-61. doi: 10.1358/dot.2023.59.2.3521876Loncharich MF, Robertson I. Anifrolumab in systemic lupus erythematosus. Drugs Today (Barc). 2023;59(2):53-61. doi: 10.1358/dot.2023.59.2.3521876Алексеева ЕИ, Денисова РВ, Валиева СИ, Бзарова ТМ, Слепцова ТВ, Чомахидзе АМ, и др. Эффективность и безопасность ритуксимаба у детей с системной красной волчанкой: результаты ретроспективного исследования серии случаев. Вопросы современной педиатрии. 2016;15(5):497-504. doi: 10.15690/vsp.v15i5.1624Alexeeva EI, Denisova RV, Valieva SI, Bzarova TM, Sleptsova TV, Chomakhidze AM, et al. Efficacy and safety of rituximab in children with systemic lupus erythematosus: Results of a retrospective study of the case series. Current Pediatrics. 2016;15(5):497-504 (In Russ.) doi: 10.15690/vsp.v15i5.1624Калашникова ЭМ, Раупов РК, Любимова НА, Кучинская ЕМ, Масалова ВВ, Исупова ЕА, и др. Опыт применения ритуксимаба у пациентов с ювенильной системной красной волчанкой: предварительные результаты двуцентрового когортного исследования. Российский вестник перинатологии и педиатрии. 2023;68(1):74-84. doi: 10.21508/1027-4065-2023-68-1-74-84Kalashnikova EM, Raupov RK, Lyubimova NA, Kuchinskaya EM, Masalova VV, Isupova EA, et al. The experience of rituximab therapy in patients with juvenile systemic lupus erythematosus: The preliminary results of two-center cohort study. Russian Bulletin of Perinatology and Pediatrics. 2023;68(1):74-84 (In Russ.) doi: 10.21508/1027-4065-2023-68-1-74-84Santimov A, Grom AA. Other biological therapies for pediatric rheumatic diseases. Handbook Syst Autoimmun Dis. 2016;11:503-525. doi: 10.1016/B978-0-444-63596-9.00024-4Santimov A, Grom AA. Other biological therapies for pediatric rheumatic diseases. Handbook Syst Autoimmun Dis. 2016;11:503-525. doi: 10.1016/B978-0-444-63596-9.00024-4Plüß M, Tampe B, Niebusch N, Zeisberg M, Müller GA, Korsten P. Clinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus. Front Med (Lausanne). 2020;7:222. doi: 10.3389/fmed.2020.00222Plüß M, Tampe B, Niebusch N, Zeisberg M, Müller GA, Korsten P. Clinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus. Front Med (Lausanne). 2020;7:222. doi: 10.3389/fmed.2020.00222Cheng H, Zhang XY, Yang HD, Yu Z, Yan CL, Gao C, et al. Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus. Front Immunol. 2022;13:911730. doi: 10.3389/fimmu.2022.911730Cheng H, Zhang XY, Yang HD, Yu Z, Yan CL, Gao C, et al. Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus. Front Immunol. 2022;13:911730. doi: 10.3389/fimmu.2022.911730Bangert E, Wakani L, Merchant M, Strand V, Touma Z. Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: Review of clinical studies. Patient Relat Outcome Meas. 2019;10:1-7. doi: 10.2147/PROM.S134326Bangert E, Wakani L, Merchant M, Strand V, Touma Z. Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: Review of clinical studies. Patient Relat Outcome Meas. 2019;10:1-7. doi: 10.2147/PROM.S134326Xu Y, Xu JW, Wang YJ, Tung TH, Chien CW. Belimumab combined with standard therapy does not increase adverse effects compared with a control treatment: A systematic review and metaanalysis of randomised controlled trials. Int Immunopharmacol. 2022;109:108811. doi: 10.1016/j.intimp.2022.108811Xu Y, Xu JW, Wang YJ, Tung TH, Chien CW. Belimumab combined with standard therapy does not increase adverse effects compared with a control treatment: A systematic review and metaanalysis of randomised controlled trials. Int Immunopharmacol. 2022;109:108811. doi: 10.1016/j.intimp.2022.108811

The authors declare that there are no conflicts of interest present.